剂型：片剂 规格：50mg、0.2g 注册分类：化学药品 药品批准文号：国药准字H20250041、国药准字H20250042 协议有效期：自2026年1月1日至2027年12月31日 二、该药品相关的信息 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 2025年12月7日，国家医保局、人力资源社会保障部发布《国家基本医疗保险、生育保险和工伤保险药 品目录（2025年）》（以下简称"《国家医保目录》"），自2026年1月1日起执行。上海医药集团股份有 限公司（以下简称"公司"）下属上海上药中西制药有限公司（以下简称"上药中西"）的氨磺必利口崩片 （以下简称"该药品"） 通过国家医保谈判，成功纳入《国家医保目录》。具体情况如下： 一、该药品基本情况 药品名称：氨磺必利口崩片 IQVIA数据库显示，2024年氨磺必利口服制剂的医院采购金额为人民币16,841万元。 三、对上市公司影响及风险提示 上药中西的氨磺必利口崩片成功纳入《国家医保目录》，有利于扩大该药品的市场份额，提升市场竞争 力，同时为公司其他产品开展相关工作积累 ...

Major Events - GuoXia Technology (02655) plans to conduct an IPO from December 8 to December 11, offering 33.85 million H-shares and introducing cornerstone investors such as Huikai Hong Kong [1] - Basilea Pharmaceutica AG (02616) has its drug Pujihua® (Pralsetinib Capsules) included in the National Medical Insurance Directory for 2025 [1] - Four Seasons Pharmaceutical (00460) sees its innovative drug XuanYueNing® included in the National Basic Medical Insurance Drug List for the first time [1] - Shanghai Pharmaceuticals (02607) successfully negotiates and includes Amisulpride Orally Disintegrating Tablets in the National Medical Insurance Directory [1] - Hansoh Pharmaceutical (03692) has its innovative drug Amelotex® approved for two new indications in the updated 2025 National Medical Insurance Directory [1] - Xiansheng Pharmaceutical (02096) sees EnzeShu® and EnDu® included in the updated National Medical Insurance Drug List [1] - Hutchison China MediTech (00013) has its drug Tazverik® included in the first edition of the National Commercial Health Insurance Innovative Drug List [1] - XuanZhu Biotechnology (02575) has its innovative drug XuanYueNing® included in the National Basic Medical Insurance Drug List for the first time [1] - Yino Pharmaceutical (02591) has its H-shares included in the list of eligible securities for the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect [1] - China Metallurgical Group (01618) and its subsidiaries plan to sell non-core business assets for approximately 60.68 billion yuan, focusing on core businesses in metallurgical engineering, non-ferrous metals, and mining engineering [1] - Cambridge Technology (06166) intends to invest a total of 405 million yuan to acquire and subscribe for shares in the Yangzhong Happiness Home Venture Capital Partnership Fund [1] Operating Performance - Dongfeng Motor Group (00489) reports cumulative automobile sales of 1.697 million units in the first 11 months, a year-on-year decrease of approximately 0.3% [2] - New天绿色能源 (00956) achieves a cumulative power generation of 1,336.89 million MWh in the first 11 months, an increase of 8.04% year-on-year [2] - Longyuan Power (00916) reports a cumulative power generation of approximately 6,909.64 million MWh in the first 11 months, a year-on-year growth of 0.41% [2] - Baolong Real Estate (01238) records a total contract sales of approximately 6.666 billion yuan in the first 11 months, a year-on-year decline of 43.2% [2]

公告显示，氨磺必利口崩片是赛诺菲（Sanofi）公司于1986年在法国上市的氨磺必利片的改良剂型，用 于治疗成人精神分裂症。2025年10月，经国家药品监督管理局批准，上药中西成为氨磺必利口崩片的上 市许可持有人。截至本公告日，中国境内氨磺必利口崩片暂无其他企业上市。 北京商报讯（记者 王寅浩 宋雨盈）12月8日，上海医药发布公告称，公司下属上海上药中西制药有限公 司的（以下简称"上药中西"）氨磺必利口崩片通过国家医保谈判，成功纳入《国家医保目录》，协议有 效期为2026年1月1日至2027年12月31日。 ...

氨磺必利口崩片是赛诺菲(Sanofi)公司于1986年在法国上市的氨磺必利片的改良剂型，用于治疗成人精 神分裂症。2025年10月，经国家药品监督管理局批准，上药中西成为氨磺必利口崩片的上市许可持有 人。截至本公告日，中国境内氨磺必利口崩片暂无其他企业上市。IQVIA数据库显示，2024年氨磺必利 口服制剂的医院采购金额为人民币16,841万元。 上药中西的氨磺必利口崩片成功纳入《国家医保目录》，有利于扩大该药品的市场份额，提升市场竞争 力，同时为公司其他产品开展相关工作积累宝贵经验。 上海医药（601607）(02607)发布公告，2025年12月7日，国家医保局、人力资源社会保障部发布《国家 基本医疗保险、生育保险和工伤保险药品目录(2025年)》，自2026年1月1日起执行。上海医药集团股份 有限公司下属上海上药中西制药有限公司的氨磺必利口崩片通过国家医保谈判，成功纳入《国家医保目 录》。 ...

氨磺必利口崩片是赛诺菲(Sanofi)公司于1986年在法国上市的氨磺必利片的改良剂型，用于治疗成人精 神分裂症。2025年10月，经国家药品监督管理局批准，上药中西成为氨磺必利口崩片的上市许可持有 人。截至本公告日，中国境内氨磺必利口崩片暂无其他企业上市。IQVIA数据库显示，2024年氨磺必利 口服制剂的医院采购金额为人民币16,841万元。 上药中西的氨磺必利口崩片成功纳入《国家医保目录》，有利于扩大该药品的市场份额，提升市场竞争 力，同时为公司其他产品开展相关工作积累宝贵经验。 智通财经APP讯，上海医药(02607)发布公告，2025年12月7日，国家医保局、人力资源社会保障部发布 《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》，自2026年1月1日起执行。上海医药集 团股份有限公司下属上海上药中西制药有限公司的氨磺必利口崩片通过国家医保谈判，成功纳入《国家 医保目录》。 ...

截至本公告日，中国境内氨磺必利口崩片暂无其他企业上市。 IQVIA数据库显示，2024年氨磺必利口服制剂的医院采购金额为人民币16,841万元。 氨磺必利口崩片是赛诺菲(Sanofi)公司于1986年在法国上市的氨磺必利片的改良剂型，用于治疗成人精 神分裂症。2025年10月，经国家药品监督管理局批准，上药中西成为氨磺必利口崩片的上市许可持有 人。 格隆汇12月8日丨上海医药(02607.HK)公布，2025年12月7日，国家医保局、人力资源社会保障部发布 《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》(以下简称"《国家医保目录》")，自 2026年1月1日起执行。公司下属上海上药中西制药有限公司(以下简称"上药中西")的氨磺必利口崩片(以 下简称"该药品")通过国家医保谈判，成功纳入《国家医保目录》。 ...

格隆汇12月8日丨上海医药(601607.SH)公布，2025年12月7日，国家医保局、人力资源社会保障部发布 《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》（简称"《国家医保目录》"），自 2026年1月1日起执行。下属上海上药中西制药有限公司（简称"上药中西"）的氨磺必利口崩片（简 称"该药品"）通过国家医保谈判，成功纳入《国家医保目录》。 氨磺必利口崩片是赛诺菲（Sanofi）公司于1986年在法国上市的氨磺必利片的改良剂型，用于治疗成人 精神分裂症。2025年10月，经国家药品监督管理局批准，上药中西成为氨磺必利口崩片的上市许可持有 人。 ...

上海医药(601607.SH)公告称，公司下属上海上药中西制药有限公司的氨磺必利口崩片通过国家医保谈 判，成功纳入《国家医保目录》，协议有效期为自2026年1月1日至2027年12月31日。氨磺必利口崩片是 赛诺菲（Sanofi）公司于1986年在法国上市的氨磺必利片的改良剂型，用于治疗成人精神分裂症。2025 年10月，经国家药品监督管理局批准，上药中西成为氨磺必利口崩片的上市许可持有人。截至本公告 日，中国境内氨磺必利口崩片暂无其他企业上市。IQVIA数据库显示，2024年氨磺必利口服制剂的医院 采购金额为1.68亿元。 ...

人民财讯12月8日电，上海医药（601607）12月8日公告，公司下属公司上药中西的氨磺必利口崩片通过 国家医保谈判，成功纳入《国家医保目录》。氨磺必利口崩片是赛诺菲(Sanofi)公司于1986年在法国上 市的氨磺必利片的改良剂型，用于治疗成人精神分裂症。 ...

Major Events - Cambridge Technology (06166) sets the offer price for H-shares at HKD 68.88 per share [1] - Sany Heavy Industry (06031) sets the offer price for H-shares at HKD 21.30 per share [1] - Hengrui Medicine (01276) receives approval for the launch of HR20031 tablets [1] - Shanghai Pharmaceuticals (02607) subsidiary becomes the holder of the marketing authorization for amisulpride orally disintegrating tablets [1] - Fosun Pharma (02196) receives registration approval for Delarobert tablets and Delarobert granules [1] - WuXi AppTec (02359) plans to sell 100% equity of Kande Hongyi and Jinshi Medicine [1] - Hengfu Holdings (00643) receives a buyout offer at a discount of approximately 79.20% and will resume trading on October 27 [1] Operating Performance - Chifeng Jilong Gold Mining (06693) reports Q3 net profit of CNY 951 million, a year-on-year increase of 140.98% [1] - WuXi AppTec (02359) reports a net profit of CNY 12.076 billion for the first three quarters, up 84.84% year-on-year [1] - Huaxin Cement (06655) reports a net profit of CNY 2.004 billion for the first three quarters, a year-on-year increase of 76.01% [1] - Luoyang Molybdenum (03993) reports a net profit of approximately CNY 14.28 billion for the first three quarters, up 72.61% year-on-year [1] - Goldwind Technology (02208) reports a net profit of approximately CNY 2.584 billion for the first three quarters, a year-on-year increase of 44.21% [1] - CITIC Securities (06030) reports a net profit of approximately CNY 23.159 billion for the first three quarters, up 37.86% year-on-year [1] - Kingdee International (00268) reports annual recurring revenue of approximately CNY 3.86 billion from subscription services for the first three quarters, a year-on-year increase of about 18% [1] - China Nonferrous Mining (01258) estimates a profit of approximately USD 356 million for the first three quarters, a year-on-year increase of about 13% [1] - Chongqing Bank (01963) reports a net profit of CNY 4.879 billion for the first three quarters, a year-on-year increase of 10.19% [1] - China Resources Cement (01313) reports a profit attributable to shareholders of CNY 331 million for the first three quarters, a year-on-year increase of 7.3% [1] - China Shenhua Energy (01088) reports a net profit of CNY 41.366 billion for the first three quarters, a year-on-year decrease of 13.8% [1] - Haohai Biological Technology (06826) reports a net profit of approximately CNY 305 million for the first three quarters, a year-on-year decrease of 10.63% [1] - Great Wall Motors (02333) reports a net profit of CNY 2.298 billion for the third quarter, a year-on-year decrease of 31.23% [1] - China Heart and Heart Fertilizer (01866) reports a net profit of approximately CNY 800 million for the first three quarters, a year-on-year decrease of 47.86% [1] - China National Building Material (03323) reports a net profit of CNY 2.96 billion for the first three quarters [1] - GAC Group (02238) reports a net loss of approximately CNY 4.312 billion for the first three quarters, a shift from profit to loss year-on-year [1] - China Overseas Development (00688) reports revenue of CNY 103 billion and operating profit of CNY 13.15 billion for the first three quarters [1] - Haifeng International (01308) reports revenue of approximately USD 2.459 billion for the first three quarters, a year-on-year increase of approximately 16.6% [1] - China Energy Engineering (03996) reports a cumulative new contract amount of CNY 992.775 billion for the first three quarters, a year-on-year increase of 0.4% [1] E-commerce Performance - Li Ning (02331) reports high double-digit growth in its e-commerce virtual store business for the third quarter [2]